echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Ann Rheum Dis: Efficacy and safety of brodazumab on axial spondyloarthritis

    Ann Rheum Dis: Efficacy and safety of brodazumab on axial spondyloarthritis

    • Last Update: 2021-08-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bridalumab is a human monoclonal antibody that can bind to and block the signal mediated by the IL-17 receptor
    .
    This study explored the efficacy and safety of brodazumab in the treatment of axial spondyloarthritis (axSpA)


    .


    Bridalumab is a human monoclonal antibody that can bind to and block the signal mediated by the IL-17 receptor


    This is a multi-center, placebo-controlled Phase 3 study (NCT02985983).


    The axSpA patients were randomly divided into groups according to a 1:1 ratio.


    This is a multi-center, placebo-controlled Phase 3 study (NCT02985983).


    The results are as follows: the ASAS 40 response rate (95%CI) of the brodazumab group was 43.


    8% (35/80; 32.


    The results are as follows: the ASAS 40 response rate (95%CI) of the brodazumab group was 43.


    Figure: Response rates of ASAS40 and ASAS20 in patients with spondyloarthritis

    Figure: Response rate of ASAS40 and ASAS20 in patients with spondyloarthritis Figure: Response rate of ASAS40 and ASAS20 in patients with spondyloarthritis

    For patients with active axSpA, brodazumab showed significant efficacy at the 16th week


    .


    For patients with active axSpA, brodazumab showed significant efficacy at the 16th week


     

    Original source:

    Original source: Original source:

    James Cheng-Chung Wei.


    Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.


    James Cheng-Chung Wei.


     

     

     

     

     

     

     

     

     

     

     

     

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.